Goldman Sachs Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575

Benzinga Newsdesk www.benzinga.com Positive 87.6%

Neg 0% Neu 0% Pos 87.6%

Goldman Sachs analyst Kevin Strang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $470 to $575.